期刊文献+

RNAi沉默c-erbB-2、c-raf-1表达对人舌鳞癌Tca8113细胞的干预作用 被引量:1

RNA interference c-erbB-2 and c-raf-1 genes expression combined transfection in the Tca8113 cell lines
下载PDF
导出
摘要 目的 :探讨应用RNA干扰技术沉默c-erbB - 2、c -raf- 1基因表达 ,研究其对人舌鳞癌Tca8113细胞增殖的抑制作用及其分子机制。方法 :实验分成 3组 :空白对照组、正常对照组、c -erbB - 2、c-raf- 1dsRNA联合干扰组。脂质体转染后不同时间分别进行MTT试验、电镜检测、RT -PCR ,以观察不同条件处理后各组细胞的增殖、凋亡、细胞周期、mRNA及蛋白质表达有无差别。结果 :c-erbB - 2、c -raf- 1dsRNA联合干扰组 ,转染 72h的OD值为 0 .0 73(P <0 .0 0 5 ) ,增殖抑制率达到了94 .5 % ,凋亡率为 76 .5 % (P <0 .0 1) ,明显地下调c-erbB - 2与c -raf- 1基因mRNA及其蛋白质的表达水平。结论 :在舌癌Tca8113细胞株增殖的抑制作用研究中 ,c-erbB - 2、c -raf- 1dsRNA联合干扰具有显著沉默c -erbB - 2、c -raf- 1基因表达。 Objective:To investigate the proliferating inhibition and the mechanisms of dsRNA interference c-erbB-2 and c-raf-1 genes expression combined transfection in the human tongue carcinoma Tca8113 cell lines.Methods:There were 3 groups in our study,control group,normal control group and RNAi experimental group.At different time after liposome-mediated transfection,the cell proliferation,apoptosis,mRNA level,protein expressing level and cell cycle were observed by MTT,RT-PCR and electronic microscope.Results:According to the results of RNAi experimental group,the OD-value were 0.073( P <0.005)transfected after 72h;the inhibitory rate of proliferation were 94.5%;the apoptosis rate were 76.5% ( P <0.01 ) and the level of mRNA and protein were decreased statistically in both c-erbB-2 and c-raf-1.Conclusion:These results suggest that c-erbB-2 and c-raf-1 dsRNA effects of silencing c-erbB-2 and c-raf-1 genes expression combined transfection of tongue carcinoma.
出处 《重庆医科大学学报》 CAS CSCD 2004年第5期567-571,共5页 Journal of Chongqing Medical University
基金 国家自然科学基金资助项目 (编号 :3 0 0 70 2 3 0 )
关键词 舌鳞癌 RNA干扰 转录后沉默(PTGS) 联合转染 Tongue carcinoma RNA interfering Post transcriptional gene silencing(PTGS) Combined transfection
  • 相关文献

参考文献9

  • 1Nagler RM, Kemer H, Laufer D, et al. Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl - 2, c - erbB- 2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study[J]. Cancer,200
  • 2Kennerdell JR, Carthew RW. Use of dsRNA - mediatod genehc interference to demonstrate that frizzled and frizzled2act in the wingless pathway[J]. Cell, 1998; 95 (7): 1017 -1026.
  • 3Tuschel T, Zamore PD, Lehmann R, et al. Targeted mRNA degradation by double- strannded RNA in vitro[J ]. Genes Der, 1999; 13(24) :3191 - 3197.
  • 4Elbashir SM, Lendeckel W, Tuschel T. RNA interference is mediated by 21 - 22 - nueleotide RNAs[J]. CJene Der,2001;15(2): 188 - 200.
  • 5Lipanli C, Wei Q, Paterson BM. RNAi as random degradation PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate, new siRNA[J]. Cell, 2001; 107(3):297 - 307.
  • 6Jens Harborth, Sayda M. Elbashir, Kim Bechert, et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs[J]. Cell Sci, 2001; 114:4557 - 4565.
  • 7SM Elbashir,J Harborth,W Lendeckel,et al. Dupluxes of 21 - nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001; 411 (6836): 494 - 498.
  • 8Nagler RM, Kerner H, Ben - Eliezer S, et al. Prognostic role of apoptotic, Bcl - 2, c - erbB - 2 and p53 tumor markers in salivary gland malignancies [J]. Oneology, 2003; 64 (4): 389 -398.
  • 9Stevenson JP,Kang - Shen Yao,Gallagher M, et al. Phase I clinical pharmacokinehc and pharmacodynamic trial of the craf- 1 antisense ologonucleotide[J]. clm Oncol, 1999; 17(7):2227 - 2236.

同被引文献9

  • 1Wahl M L, Kenan D J, Gonzalez-Gronow M, et al. Angiostatin' s molecular mechanism: aspects of specificity and regulation elucidated[ J ]. J Cell Biochem, 2005, 96 (2) : 242 -261.
  • 2Hanford H A, Wong C A, Kassan H, et al. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells [ J ]. Cancer Res, 2003,63 (14) : 4275 -4280.
  • 3Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions[J]. Clin Sci (Eond), 2005, 109(3): 227-241.
  • 4Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells [ J ]. FASEB J, 2002, 16(13) : 1802 - 1804.
  • 5Beerepoot L V, Witteveen E O, Groenewegen G, et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study[ J ]. Clin Cancer Res, 2003, 9( 11 ):4025-4033.
  • 6An P, Lei H, Zhang J, et al. Suppression of ttimor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library[J]. Int J Cancer, 2004, 111 (2) : 165 -173.
  • 7Kyzas P A, Stefanou D, Agnantis N J. Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip[J]. Oral Oncol, 2004, 40(9) : 941 -947.
  • 8Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocfine growth factor for VEGF receptor-positive human tumors[ J]. Blood, 2001, 98(6) : 1904 - 1913.
  • 9Chi S L, Pizzo S V. Angiostatin is directly eytotoxie to tumor cells at low extracellular pH : a mechanism dependent on cell surface-associated ATP synthase [ J ]. Cancer Res,2006,66 (2) : 875 -882.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部